TRVI Trevi Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why TRVI matters now
Trevi Therapeutics, Inc. (TRVI) is a US stock in Healthcare. The latest InvestLog snapshot shows $17.84 with -3.04% on the session and $2.53B in market capitalization; recent performance reads 1-month +29.98% and YTD +37.46%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-13.2M, and EPS of $-0.09. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -1.3%.
The latest indexable market news headline is "Trevi Therapeutics Announces Upcoming June and July Event Schedule" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $25.00; recent insider activity includes Heffernan Michael Thomas filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
14.56
P/S
0.00
EV/EBITDA
-53.24
DCF Value
$0.11
FCF Yield
-1.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-24.5%
ROA
-25.4%
ROIC
-30.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-13.2M | $-0.09 |
| Q4 2025 | $0.00 | $-8.3M | $-0.06 |
| FY 2025 | $0.00 | $-42.8M | $-0.29 |
| Q3 2025 | $0.00 | $-11.8M | $-0.08 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$25.00
Target (Median)
$25.00
Target Range
$20.00 - $30.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.05
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.